Loading data for PASG — first visit, this takes a few seconds.
Passage Bio Inc. (PASG)
NasdaqCM: PASG
· Real-Time Price · USD
4.44
-0.04 (-0.89%)
At close: Aug 21, 2026, 8:00 PM
4.44
+0.00%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Passage Bio Inc. (PASG) Stock Price, Analysis & Data
-0.89% (1D)
No data available
| Bid | 3.32 |
| Market Cap | 14.29M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -36.11M |
| 1.43 | |
| -11.32 | |
| n/a | |
| -0.43 | |
| P/B (ttm) | 3.21 |
| P/S (ttm) | n/a |
| Earnings Date | Mar 3, 2026 |
| Ask | 5.65 |
| Volume | 36,507 |
| Avg. Volume (20D) | 69,524 |
| Open | 4.53 |
| Previous Close | 4.48 |
| Day's Range | 4.36 - 4.72 |
| 52-Week Range | 3.29 - 20.00 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PASG
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystr...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 28, 2020
Employees 24
Stock Exchange NasdaqCM
Ticker Symbol PASG
Website https://www.passagebio.com
Financial Performance
In 2025, Passage Bio's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -45.52M, a decrease of -29.71%.
Financial StatementsEarnings Surprise
Passage Bio has released their quarterly earnings on Aug 10, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -2.44 exceeds estimates by 0.39, with 51.20% YoY growth.
Passage Bio Inc. is scheduled to release its earnings on Mar 3, 2026, after market closes.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2